Results 41 to 50 of about 430 (135)

Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. [PDF]

J Dtsch Dermatol Ges
Summary Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T‐cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C‐C chemokine receptor 4 (CCR4)‐directed monoclonal antibody ...
Assaf C, Booken N, Dippel E, Dobos G, Eich HT, Klemke CD, Mitteldorf C, Nicolay JP, Theurich S, Wobser M, Stadler R.   +10 more
europepmc   +2 more sources

Synthesis of a New Phenyl Chlormethine-Quinazoline Derivative, a Potential Anti-Cancer Agent, Induced Apoptosis in Hepatocellular Carcinoma Through Mediating Sirt1/Caspase 3 Signaling Pathway

Frontiers in Pharmacology, 2020
Quinazoline derivatives display multiple pharmacological activities and target various biological receptors. Based on the skeleton of quinazoline core, we designed and synthesized three new quinazoline-phenyl chlormethine conjugates (I–III) bearing a ...
Jia-jia Lv, Jia-jia Lv, Jia-jia Lv, Wen-ting Song, Wen-ting Song, Wen-ting Song, Xin-min Li, Xin-min Li, Xin-min Li, Jian-mei Gao, Jian-mei Gao, Jian-mei Gao, Ze-li Yuan, Ze-li Yuan, Ze-li Yuan   +14 more
doaj   +1 more source

Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings [PDF]

, 2022
Mycosis fungoides (MF) is a rare disease and is the most common form of cutaneous T cell lymphoma. Topical chlormethine (CL) gel is the first cytotoxic chemotherapy gel that was specifically developed for treatment of MF.
Evangelia Papadavid, Papadavid, Evangelia, Ulrike Wehkamp, Nikbakht, Neda, Wehkamp, Ulrike, Ardigò, Marco, Querfeld, Christiane, Neda Nikbakht, Christiane Querfeld, Marco Ardigò   +9 more
core   +1 more source

The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)

, 2022
In Europe chlormethine gel is licensed for the management of patients with mycosis fungoides of all stages. However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established.
Klemke, C.D., Max Schlaak, Claus‐Detlev Klemke, Jonak, C., Jan P. Nicolay, Marion Wobser, Trautinger, F., Assaf, C., Booken, N., Franz Trautinger, Edgar Dippel, Chalid Assaf, Dippel, E., Emmanuella Guenova, Constanze Jonak, Guenova, E., Nina Booken, Nicolay, J.P., Wobser, M., Schlaak, M.   +19 more
core   +1 more source

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations

Cancer Management and Research, 2022
Caitlin Crimp,1 Ameya Gangal,2 Erica S Tarabadkar,3 Michi M Shinohara1,4 1Division of Dermatology, University of Washington, Seattle, WA, USA; 2School of Medicine, Emory University, Atlanta, GA, USA; 3Department of Dermatology, Emory University School of
Crimp C, Gangal A, Tarabadkar ES, Shinohara MM   +3 more
doaj  

Topical chlormethine gel in the treatment of mycosis fungoides: A single‐center real‐life experience and systematic review of the literature

, 2022
Gel formulation of chlormethine (CG) has gained a preeminent role among therapies available for mycosis fungoides (MF). To evaluate the frequency of use of CG for MF treatment and to determine the limits and potentialities of CG in a real-world setting ...
Laghi, Alessandro, Sansone, Massimo, Teoli, Miriam, Ardigò, Marco, Mandel, Victor Desmond, La Malfa, Antonia Marina, Franceschini, Chiara, Musicco, Felice   +7 more
core   +1 more source

Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports

, 2021
Introduction: Chlormethine gel is a skin-directed therapy recommended for patients with early-stage mycosis fungoides (MF) cutaneous T cell lymphoma.
Lampadaki, K., Koumourtzis, M., Karagianni, F., Papadavid, E., Marinos, L.   +4 more
core   +1 more source

Current state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German ...
Inga Hansen‐Abeck, Larissa Kölln, Finn Abeck, Glenn Geidel, Stefan W. Schneider, Nina Booken   +5 more
wiley   +1 more source

Querfeld_ 202 Research Letter_Supplementary_JAAD

, 2021
Supplementary information relating to manuscript titled 'Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study' publishsed in ...
Franklin, J (via Mendeley Data)
core   +1 more source

Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert, Juliette M. Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink‐Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H. Vermeer, Constanze Jonak   +15 more
wiley   +1 more source